Intensity Therapeutics, Inc.
8 Wright Street
Suite 107
Westport
Connecticut
06880
United States
Tel: 203-682-2434
Fax: 203-664-1051
About Intensity Therapeutics, Inc.
Intensity Therapeutics is a biotechnology company whose mission is to greatly extend the lives of cancer patients. Late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases either in the blood or body tissue. Cancer is thus both a regional and a systemic disease. To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics was thus founded to develop a new approach to treat both the big and the small aspects of the disease - in situ vaccination. Using our DfuseRxSM platform, we create novel formulations of proven drugs. Our products have high diffusion and dispersion properties in tumors. When injected directly into a tumor or visible metastases these products are able to kill the tumors and create sites for an adaptive immune response. The observed adaptive immune response further increases the efficacy of our system to destroy or regress the tumor, eliminate secondary tumors and micrometastases as well. The Company demonstrated that complete regression (CR) of large tumors in mice is possible using the technology. Animals that had a CR became fully resistant to re-inoculation of the same cancer.YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Lewis H. Bender
Chief Medical Officer: Ian B. Walters, MD
60 articles about Intensity Therapeutics, Inc.
-
Intensity Therapeutics Raises $6.5 Million in Series B Financing
11/2/2018
Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors
-
Portage provides update on SalvaRx portfolio company, Intensity Therapeutics, Inc.
10/22/2018
Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a SalvaRx Limited portfolio company, Intensity Therapeutics, Inc. ("Intensity"). SalvaRx Limited holds an 8.5% equity interest in Intensity.
-
Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO Conference
5/31/2018
The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting is taking place June 1-5 in Chicago.
-
Mark A. Goldberg, MD Joins Intensity Therapeutics, Inc. Board of Directors
5/17/2018
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.
-
Intensity Therapeutics, Inc. Reports Positive Safety Data from Ongoing IT-01 Phase 1/2 Trial
2/27/2018
Study Steering Committee approves opening cohorts for dosing to deep tumors and more frequent treatment into superficial tumors
-
Intensity Therapeutics, Inc. Issued New Patents For Technology Platform
6/15/2017
-
Intensity Therapeutics, Inc. Successfully Administers INT230-6 To First Patient In A Phase I/II Trial
5/30/2017
-
Intensity Therapeutics, Inc. Reports That INT230-6 Induces Protective T-Cell Immunity In Preclinical Models
4/4/2017
-
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6
6/28/2016
-
Intensity Therapeutics, Inc. Issued First U.S. Patent For Immune-based Cancer Therapeutic Agents
6/2/2016
-
Intensity Therapeutics, Inc. Reports That INT230-6’s Anti-Cancer Mechanism Is A Combination Of Cell Death With Immune System Activation
4/19/2016
-
Intensity Therapeutics, Inc. Selected To Present At BioCentury Future Leaders Conference
3/8/2016
-
Intensity Therapeutics, Inc. Reports Anti-Cancer Immunological Effect Generated By INT230-6
3/3/2016
-
Intensity Therapeutics, Inc. Reports Anti-Cancer Immunological Effect Generated By INT230-6
3/3/2016
-
Intensity Therapeutics, Inc. Preclinical Results Show Anti-Cancer Synergy Of INT230-6 With Anti-PD-1 Compounds
11/5/2015
-
Intensity Therapeutics, Inc. Forms Scientific Advisory Board Comprised Of World-Leading Oncologists And Scientists
10/22/2015
-
Intensity Therapeutics, Inc.'s Research Selected For Presentation At The 2015 American Association for Cancer Research Annual Meeting
4/16/2015
-
Intensity Therapeutics, Inc.'s Research Selected For Presentation At The Annual National Cancer Institute Cancer Immunology And Immunotherapy Conference
10/9/2014
-
Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President And Chief Medical Officer
9/3/2014
-
Intensity Therapeutics, Inc. Awarded Cooperative Research And Development Agreement From National Cancer Institute
5/28/2014